Cargando…

Modeling the impact of delaying transcatheter aortic valve replacement for the treatment of aortic stenosis in the era of COVID-19

OBJECTIVE: The aim of this study was to model the short term and 2-year overall survival (OS) for intermediate-risk and low-risk patients with severe symptomatic aortic stenosis (AS) undergoing timely or delayed transcatheter aortic valve replacement (TAVR) during the 2019 novel coronavirus (COVID-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Freno, Daniel R., Shipe, Maren E., Levack, Melissa M., Shah, Ashish S., Deppen, Stephen A., O'Leary, Jared M., Grogan, Eric L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184875/
https://www.ncbi.nlm.nih.gov/pubmed/34124697
http://dx.doi.org/10.1016/j.xjon.2021.06.006
_version_ 1783704668434595840
author Freno, Daniel R.
Shipe, Maren E.
Levack, Melissa M.
Shah, Ashish S.
Deppen, Stephen A.
O'Leary, Jared M.
Grogan, Eric L.
author_facet Freno, Daniel R.
Shipe, Maren E.
Levack, Melissa M.
Shah, Ashish S.
Deppen, Stephen A.
O'Leary, Jared M.
Grogan, Eric L.
author_sort Freno, Daniel R.
collection PubMed
description OBJECTIVE: The aim of this study was to model the short term and 2-year overall survival (OS) for intermediate-risk and low-risk patients with severe symptomatic aortic stenosis (AS) undergoing timely or delayed transcatheter aortic valve replacement (TAVR) during the 2019 novel coronavirus (COVID-19) pandemic. METHODS: We developed a decision analysis model to evaluate 2 treatment strategies for both low-risk and intermediate-risk patients with AS during the COVID-19 novel coronavirus pandemic. RESULTS: Prompt TAVR resulted in improved 2-year OS compared with delayed intervention for intermediate-risk patients (0.81 vs 0.67) and low-risk patients (0.95 vs 0.85), owing to the risk of death or the need for urgent/emergent TAVR in the waiting period. However, if the probability of acquiring COVID-19 novel coronavirus is >55% (intermediate-risk patients) or 47% (low-risk patients), delayed TAVR is favored over prompt intervention (0.66 vs 0.67 for intermediate risk; 0.84 vs 0.85 for low risk). CONCLUSIONS: Prompt transcatheter aortic valve replacement for both intermediate-risk and low-risk patients with symptomatic severe AS results in improved 2-year survival when local healthcare system resources are not significantly constrained by the COVID-19.
format Online
Article
Text
id pubmed-8184875
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81848752021-06-08 Modeling the impact of delaying transcatheter aortic valve replacement for the treatment of aortic stenosis in the era of COVID-19 Freno, Daniel R. Shipe, Maren E. Levack, Melissa M. Shah, Ashish S. Deppen, Stephen A. O'Leary, Jared M. Grogan, Eric L. JTCVS Open Adult: Aortic Valve OBJECTIVE: The aim of this study was to model the short term and 2-year overall survival (OS) for intermediate-risk and low-risk patients with severe symptomatic aortic stenosis (AS) undergoing timely or delayed transcatheter aortic valve replacement (TAVR) during the 2019 novel coronavirus (COVID-19) pandemic. METHODS: We developed a decision analysis model to evaluate 2 treatment strategies for both low-risk and intermediate-risk patients with AS during the COVID-19 novel coronavirus pandemic. RESULTS: Prompt TAVR resulted in improved 2-year OS compared with delayed intervention for intermediate-risk patients (0.81 vs 0.67) and low-risk patients (0.95 vs 0.85), owing to the risk of death or the need for urgent/emergent TAVR in the waiting period. However, if the probability of acquiring COVID-19 novel coronavirus is >55% (intermediate-risk patients) or 47% (low-risk patients), delayed TAVR is favored over prompt intervention (0.66 vs 0.67 for intermediate risk; 0.84 vs 0.85 for low risk). CONCLUSIONS: Prompt transcatheter aortic valve replacement for both intermediate-risk and low-risk patients with symptomatic severe AS results in improved 2-year survival when local healthcare system resources are not significantly constrained by the COVID-19. Elsevier 2021-06-08 /pmc/articles/PMC8184875/ /pubmed/34124697 http://dx.doi.org/10.1016/j.xjon.2021.06.006 Text en © 2021 The Authors. Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Adult: Aortic Valve
Freno, Daniel R.
Shipe, Maren E.
Levack, Melissa M.
Shah, Ashish S.
Deppen, Stephen A.
O'Leary, Jared M.
Grogan, Eric L.
Modeling the impact of delaying transcatheter aortic valve replacement for the treatment of aortic stenosis in the era of COVID-19
title Modeling the impact of delaying transcatheter aortic valve replacement for the treatment of aortic stenosis in the era of COVID-19
title_full Modeling the impact of delaying transcatheter aortic valve replacement for the treatment of aortic stenosis in the era of COVID-19
title_fullStr Modeling the impact of delaying transcatheter aortic valve replacement for the treatment of aortic stenosis in the era of COVID-19
title_full_unstemmed Modeling the impact of delaying transcatheter aortic valve replacement for the treatment of aortic stenosis in the era of COVID-19
title_short Modeling the impact of delaying transcatheter aortic valve replacement for the treatment of aortic stenosis in the era of COVID-19
title_sort modeling the impact of delaying transcatheter aortic valve replacement for the treatment of aortic stenosis in the era of covid-19
topic Adult: Aortic Valve
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184875/
https://www.ncbi.nlm.nih.gov/pubmed/34124697
http://dx.doi.org/10.1016/j.xjon.2021.06.006
work_keys_str_mv AT frenodanielr modelingtheimpactofdelayingtranscatheteraorticvalvereplacementforthetreatmentofaorticstenosisintheeraofcovid19
AT shipemarene modelingtheimpactofdelayingtranscatheteraorticvalvereplacementforthetreatmentofaorticstenosisintheeraofcovid19
AT levackmelissam modelingtheimpactofdelayingtranscatheteraorticvalvereplacementforthetreatmentofaorticstenosisintheeraofcovid19
AT shahashishs modelingtheimpactofdelayingtranscatheteraorticvalvereplacementforthetreatmentofaorticstenosisintheeraofcovid19
AT deppenstephena modelingtheimpactofdelayingtranscatheteraorticvalvereplacementforthetreatmentofaorticstenosisintheeraofcovid19
AT olearyjaredm modelingtheimpactofdelayingtranscatheteraorticvalvereplacementforthetreatmentofaorticstenosisintheeraofcovid19
AT groganericl modelingtheimpactofdelayingtranscatheteraorticvalvereplacementforthetreatmentofaorticstenosisintheeraofcovid19